Hypoglycemia measured by flash glucose monitoring system predicts liver-related events in chronic liver disease patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 08 2023
23 08 2023
Historique:
received:
01
03
2023
accepted:
18
08
2023
medline:
25
8
2023
pubmed:
24
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Impaired glucose tolerance, glucose fluctuations, and hypoglycemia have been observed in patients with chronic liver disease (CLD). The flash glucose monitoring (FGM) system, which recognises continuous and dynamic glucose changes in real time, is used in daily clinical practice. This study aimed to examine the association between glucose fluctuations and hypoglycemia, as measured by the FGM system, and liver-related events. Seventy-two patients with CLD and type 2 DM who had their blood glucose measured using Freestyle Libre Pro between April 2017 and July 2018 at our institution were enrolled in this retrospective study. We assessed the results of the FGM system measurements and liver-related events, as defined by gastrointestinal bleeding, infection, ascites, encephalopathy, and liver-related death. The standard deviation (SD) of mean glucose as measured by the FGM system was 41.55 mg/dl, and hypoglycemia was observed in 48.6% (35/72) of the patients. Liver-related event-free survival was not significant when stratified based on SD; however, the event-free survival was significantly lower when stratified by hypoglycemia (p = 0.007). In a multivariate analysis using the Cox proportional hazards model, Child-Pugh class B [Hazards ratio (HR) 2.347 (95% confidence interval (CI): 1.042-5.283), p = 0.039] and hypoglycemia [HR 2.279 (95% CI: 1.064-4.881), p = 0.034] were identified as factors contributing to event-free survival. Hypoglycemia, as determined by the FGM system, was identified as a significant factor that was closely associated with liver-related events. In addition to measuring glucose levels, the FGM system is useful in predicting the occurrence of liver-related events.
Identifiants
pubmed: 37612434
doi: 10.1038/s41598-023-40910-2
pii: 10.1038/s41598-023-40910-2
pmc: PMC10447444
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Blood Glucose
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13791Informations de copyright
© 2023. Springer Nature Limited.
Références
Petrides, A. S. & DeFronzo, R. A. Glucose metabolism in cirrhosis: A review with some perspectives for the future. Diabetes Metab. Rev. 5, 691–709 (1989).
doi: 10.1002/dmr.5610050805
pubmed: 2693018
Bianchi, G. et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 20, 119–125 (1994).
pubmed: 8020880
El-Serag, H. B., Tran, T. & Everhart, J. E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460–468 (2004).
doi: 10.1053/j.gastro.2003.10.065
pubmed: 14762783
Imano, E., Nishida, T., Shibata, M. & Kanda, T. Significance of oral glucose tolerance test for the diagnosis of diabetes mellitus in patients with liver cirrhosis. Intern. Med. 38, 918 (1999).
doi: 10.2169/internalmedicine.38.918
pubmed: 10563758
Kishimoto, M. & Noda, M. Verification of glycemic profiles using continuous glucose monitoring: Cases with steroid use, liver cirrhosis, enteral nutrition, or late dumping syndrome. J. Med. Invest. 62, 1–10 (2015).
doi: 10.2152/jmi.62.1
pubmed: 25817276
Haraguchi, M. et al. Glucose fluctuations reduce quality of sleep and of life in patients with liver cirrhosis. Hepatol. Int. 11, 125–131 (2017).
doi: 10.1007/s12072-016-9762-1
pubmed: 27624504
Battelino, T. et al. Continuous glucose monitoring and metrics for clinical trials: An international consensus statement. Lancet Diabetes Endocrinol. 11, 42–57 (2023).
doi: 10.1016/S2213-8587(22)00319-9
pubmed: 36493795
Marling, C. R., Shubrook, J. H., Vernier, S. J., Wiley, M. T. & Schwartz, F. L. Characterizing blood glucose variability using new metrics with continuous glucose monitoring data. J. Diabetes Sci. Technol. 5, 871–878 (2011).
doi: 10.1177/193229681100500408
pubmed: 21880228
pmcid: 3192592
Service, F. J. et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19, 644–655 (1970).
doi: 10.2337/diab.19.9.644
pubmed: 5469118
Owen, O. E. et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J. Clin. Invest. 72, 1821–1832 (1983).
doi: 10.1172/JCI111142
pubmed: 6630528
pmcid: 370471
Tolman, K. G., Fonseca, V., Dalpiaz, A. & Tan, M. H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30, 734–743 (2007).
doi: 10.2337/dc06-1539
pubmed: 17327353
Zhou, J. et al. Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care 32, 1188–1193 (2009).
doi: 10.2337/dc09-0076
pubmed: 19389816
pmcid: 2699703
Honda, F. et al. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. PLoS ONE 13, e0195028 (2018).
doi: 10.1371/journal.pone.0195028
pubmed: 29614124
pmcid: 5882130
Kim, Y., Rajan, K. B., Sims, S. A., Wroblewski, K. E. & Reutrakul, S. Impact of glycemic variability and hypoglycemia on adverse hospital outcomes in non-critically ill patients. Diabetes Res. Clin. Pract. 103, 437–443 (2014).
doi: 10.1016/j.diabres.2013.11.026
pubmed: 24456994
Papachristoforou, E., Lambadiari, V., Maratou, E. & Makrilakis, K. Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications. J. Diabetes Res. 2020, 7489795 (2020).
doi: 10.1155/2020/7489795
pubmed: 33123598
pmcid: 7585656
Hung, T. H., Tseng, C. W., Tsai, C. C. & Lee, H. F. Prognosis of hypoglycemia episode in cirrhotic patients during hospitalization. BMC Gastroenterol. 21, 319 (2021).
doi: 10.1186/s12876-021-01895-2
pubmed: 34372791
pmcid: 8351368
Olson, J. C. et al. Intensive care of the patient with cirrhosis. Hepatology 54, 1864–1872 (2011).
doi: 10.1002/hep.24622
pubmed: 21898477
Furukawa, M., Kinoshita, K., Yamaguchi, J., Hori, S. & Sakurai, A. Sepsis patients with complication of hypoglycemia and hypoalbuminemia are an early and easy identification of high mortality risk. Intern. Emerg. Med. 14, 539–548 (2019).
doi: 10.1007/s11739-019-02034-2
pubmed: 30729384
pmcid: 6536472
Coman, L. I., Coman, O. A., Badarau, I. A., Paunescu, H. & Ciocirlan, M. Association between liver cirrhosis and diabetes mellitus: A review on hepatic outcomes. J. Clin. Med. 10, 262 (2021).
doi: 10.3390/jcm10020262
pubmed: 33445629
pmcid: 7827383
Rosenblatt, R. et al. Uncontrolled diabetes mellitus increases risk of infection in patients with advanced cirrhosis. Dig. Liver Dis. 53, 445–451 (2021).
doi: 10.1016/j.dld.2020.10.022
pubmed: 33153928
Galindo, R. J. et al. Comparison of the freestyle libre pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen. Diabetes Care 43, 2730–2735 (2020).
doi: 10.2337/dc19-2073
pubmed: 32641372
pmcid: 7809713
Koga, M. & Kasayama, S. Clinical impact of glycated albumin as another glycemic control marker. Endocr. J. 57, 751–762 (2010).
doi: 10.1507/endocrj.K10E-138
pubmed: 20724796
Fukushima, H. et al. Nocturnal branched-chain amino acid administration improves protein metabolism in patients with liver cirrhosis: Comparison with daytime administration. JPEN J. Parenter. Enteral. Nutr. 27, 315–322 (2003).
doi: 10.1177/0148607103027005315
pubmed: 12971730
Park, C. & Le, Q. A. The effectiveness of continuous glucose monitoring in patients with type 2 diabetes: A systematic review of literature and meta-analysis. Diabetes Technol. Ther. 20, 613–621 (2018).
doi: 10.1089/dia.2018.0177
pubmed: 30095980